Last updated: September 26, 2026
Gedatolisib is an investigational intravenous PI3K/mTOR inhibitor with no FDA approval, no commercial product revenue, no Orange Book listing, and no generic or biosimilar market. Its value depends on Phase 3 execution in HR-positive, HER2-negative metastatic breast cancer, differentiation from approved pathway inhibitors, and the ability to manage class-related toxicities. As of June 2024, gedatolisib remained a development-stage asset rather than a marketed pharmaceutical product.
What is gedatolisib and how does it work?
Gedatolisib, also known as PF-05212384, is a pan-class I PI3K and mTOR inhibitor. It is designed to inhibit both PI3K signaling and the mTOR pathway, which are involved in tumor-cell growth, survival, proliferation, and endocrine-therapy resistance.
The asset is being developed primarily in advanced or metastatic HR-positive, HER2-negative breast cancer. The leading development strategy combines gedatolisib with fulvestrant, with or without the CDK4/6 inhibitor palbociclib, after disease progression on prior endocrine therapy and CDK4/6 inhibition.
Its commercial thesis rests on four factors:
- Treating patients after CDK4/6 inhibitor failure.
- Addressing pathway activation beyond the narrower PIK3CA-mutated population.
- Combining pathway inhibition with endocrine therapy.
- Potentially delaying or replacing chemotherapy in later-line disease.
Gedatolisib is administered intravenously, which creates a logistical disadvantage relative to oral agents such as alpelisib and capivasertib. Its broader pathway coverage may support efficacy, but it can also increase toxicity and treatment-management requirements.
What is the FDA regulatory status of gedatolisib?
Gedatolisib has no FDA approval as of June 2024. It has no approved indication, commercial label, established dosing regimen, or FDA-recognized exclusivity period.
| Regulatory item |
Gedatolisib status |
| FDA approval |
None |
| Approved indication |
None |
| NDA or BLA approval |
None publicly established |
| Orange Book listing |
None |
| FDA-approved formulation |
None |
| Generic availability |
None |
| Biosimilar relevance |
Not applicable |
| Current status |
Clinical development |
| Lead disease area |
HR-positive, HER2-negative advanced breast cancer |
The regulatory pathway is materially different from that of approved PI3K or AKT-pathway drugs. Gedatolisib must establish a clinically meaningful benefit against contemporary standards of care while demonstrating a tolerable safety profile for long-term combination treatment.
What Phase 3 trial is evaluating gedatolisib?
The principal late-stage program is VIKTORIA-1, a Phase 3 study in patients with HR-positive, HER2-negative advanced or metastatic breast cancer previously treated with endocrine therapy and a CDK4/6 inhibitor.
The trial evaluates gedatolisib in combination with fulvestrant, with or without palbociclib, against physician's-choice chemotherapy. The study is intended to test whether continued pathway and endocrine blockade can improve outcomes after CDK4/6 inhibitor progression.
| Program element |
Development implication |
| Disease |
HR-positive, HER2-negative advanced or metastatic breast cancer |
| Prior treatment |
Endocrine therapy and CDK4/6 inhibition |
| Investigational backbone |
Gedatolisib plus fulvestrant |
| Combination strategy |
With or without palbociclib |
| Comparator |
Physician's-choice chemotherapy |
| Primary commercial question |
Can gedatolisib delay chemotherapy after CDK4/6 failure? |
| Main clinical risk |
Efficacy and tolerability of broad PI3K/mTOR inhibition |
The study places gedatolisib in a commercially important treatment setting. CDK4/6 inhibitors are widely used in first-line HR-positive/HER2-negative metastatic breast cancer, creating a large post-CDK4/6 population. The competitive challenge is that multiple targeted therapies are entering the same treatment sequence.
How does gedatolisib compare with approved breast cancer pathway inhibitors?
Gedatolisib competes with drugs that target overlapping signaling pathways but have different biomarker requirements, dosing routes, and toxicity profiles.
| Drug |
Target |
FDA status as of June 2024 |
Typical positioning |
Key distinction |
| Gedatolisib |
PI3K and mTOR |
Investigational |
Post-CDK4/6 development |
Intravenous, broad pathway inhibition |
| Alpelisib, Piqray |
PI3K-alpha |
Approved |
PIK3CA-mutated HR-positive/HER2-negative disease |
Oral, biomarker-selected |
| Capivasertib, Truqap |
AKT |
Approved in November 2023 |
Alterations in PIK3CA, AKT1, or PTEN with fulvestrant |
Oral, AKT-pathway inhibition |
| Everolimus, Afinitor |
mTORC1 |
Approved |
Endocrine-resistant HR-positive disease |
Oral, established mTOR inhibitor |
| Elacestrant, Orserdu |
Estrogen receptor degrader |
Approved |
ESR1-mutated disease after endocrine therapy |
Oral, non-PI3K mechanism |
| Chemotherapy |
Multiple targets |
Established |
Later-line or visceral disease |
Broad use, but greater systemic burden |
Gedatolisib may have an advantage if its efficacy is not restricted to a single genomic alteration. Alpelisib requires a PIK3CA mutation for its principal breast cancer indication. Capivasertib has a biomarker-defined indication involving PIK3CA, AKT1, or PTEN alterations. Gedatolisib could address patients with pathway activation that is not captured by those genomic tests.
That advantage is uncertain. Broader pathway inhibition does not automatically produce superior clinical outcomes. The pivotal issue is whether the drug can deliver better progression-free survival, overall survival, or chemotherapy delay without creating unacceptable metabolic, gastrointestinal, dermatologic, or pulmonary toxicity.
What are the main market opportunities for gedatolisib?
The largest addressable opportunity is the post-CDK4/6 treatment market in HR-positive, HER2-negative metastatic breast cancer.
The commercial opportunity has several positive characteristics:
- HR-positive/HER2-negative disease is the largest breast cancer subtype.
- CDK4/6 inhibitors are standard first-line therapy for many metastatic patients.
- Resistance after CDK4/6 treatment creates a recurring second-line and later-line market.
- Patients and physicians have incentives to delay cytotoxic chemotherapy.
- Combination therapy can support longer treatment duration if tolerability is acceptable.
The market is also crowded. Patients after CDK4/6 inhibitor progression can receive endocrine combinations, targeted therapies, antibody-drug conjugates, oral selective estrogen receptor degraders, chemotherapy, and clinical-trial therapies. Reimbursement will depend on the label, biomarker requirements, comparative evidence, infusion burden, and total treatment cost.
Gedatolisib's most defensible commercial position would be a post-CDK4/6 regimen that produces clinically meaningful benefit across a broad patient population and preserves endocrine sensitivity while postponing chemotherapy.
What are the principal safety and commercial risks?
PI3K and mTOR inhibition has a well-established toxicity burden. Relevant risks include hyperglycemia, rash, diarrhea, stomatitis, nausea, fatigue, infections, pneumonitis, and treatment interruptions. Combination with fulvestrant and palbociclib may increase monitoring and supportive-care requirements.
Metabolic toxicity
Hyperglycemia is a major commercial issue for the class. Alpelisib's use is limited in part by the need for glucose monitoring and management. A broad PI3K/mTOR inhibitor that causes clinically significant hyperglycemia could face similar constraints, especially in older patients with diabetes or metabolic syndrome.
Infusion burden
An intravenous regimen requires administration-site capacity, chair time, premedication protocols, and additional healthcare-system resources. Oral competitors are easier to distribute and administer. The burden may be acceptable if efficacy is materially better, but it weakens pricing power if clinical outcomes are merely comparable.
Combination complexity
The proposed use with fulvestrant and potentially palbociclib produces a multi-drug regimen. This may improve efficacy but can complicate adherence, monitoring, dose modification, and payer review.
Late-line treatment competition
Later-line breast cancer treatment is moving toward biomarker-defined therapies and antibody-drug conjugates. If those therapies produce substantial response rates or survival gains, gedatolisib may be relegated to a narrower sequencing position.
What is the financial trajectory of gedatolisib?
Gedatolisib has no reported product sales because it is not approved. Its financial trajectory is therefore an investment and development-cost story rather than a revenue-growth story.
| Financial category |
Current assessment |
| Product revenue |
Zero before approval |
| Commercial gross margin |
Not applicable |
| Royalty revenue |
No marketed-product royalty stream publicly established |
| Development spending |
Ongoing clinical and regulatory expenditure |
| Near-term cash driver |
Financing, licensing, collaboration, or corporate funding |
| Value inflection |
Phase 3 data and regulatory progress |
| Downside trigger |
Trial failure, safety signal, or inability to differentiate |
| Upside trigger |
Positive Phase 3 efficacy with manageable toxicity |
For a development-stage asset, enterprise value is driven by probability-adjusted future cash flows. The principal variables are:
- Probability of Phase 3 success.
- Probability of regulatory approval.
- Duration of market exclusivity.
- Addressable patient population.
- Net price and reimbursement.
- Treatment duration.
- Cost of goods for intravenous manufacturing.
- Post-marketing safety obligations.
- Competitive erosion from targeted agents and antibody-drug conjugates.
The financial profile is asymmetric. Before approval, the asset produces costs without product revenue. After a successful approval, the value could rise sharply because the drug would enter a large treatment market. A failed or inconclusive Phase 3 study could reduce the asset's value substantially because the program would have limited near-term alternative indications.
Who owns or develops gedatolisib?
Gedatolisib was developed within Pfizer's research portfolio and has been advanced in later-stage development through a collaboration and licensing structure involving Celcuity. Public corporate disclosures identify Celcuity as the company responsible for advancing the clinical program under rights obtained from Pfizer.
The economics of the relationship are important but should not be equated with current revenue. Licensing arrangements for an investigational drug typically allocate development responsibilities and may include upfront payments, development milestones, regulatory milestones, commercial milestones, royalties, or rights by territory. Unless a company reports a specific payment or obligation in a filing, the existence of a license does not establish a realized financial benefit.
The program's value is therefore linked to both clinical performance and the contractual allocation of future economics between the parties.
What patents protect gedatolisib?
Gedatolisib has no Orange Book patent protection because it has no FDA-approved product. Its patent position must instead be evaluated through issued patents and pending applications covering the active compound, salts, formulations, methods of treatment, combinations, and manufacturing processes.
At the development stage, the key patent categories are:
| Patent category |
Strategic purpose |
| Composition of matter |
Protects the gedatolisib molecule and chemical variants |
| Pharmaceutical composition |
Covers drug product formulations and excipients |
| Method of treatment |
Protects use in breast cancer and other diseases |
| Combination therapy |
Covers use with fulvestrant, palbociclib, or related agents |
| Biomarker selection |
May protect treatment of pathway-activated or biomarker-defined patients |
| Manufacturing process |
Protects scalable synthesis and impurity control |
| Formulation and delivery |
May address intravenous stability, concentration, or administration |
No generic applicant can file an Abbreviated New Drug Application based on an Orange Book-listed patent until gedatolisib is approved and listed. Paragraph IV litigation is therefore not currently a commercial risk for the asset.
Patent value will depend on the expiration date and enforceability of the composition-of-matter rights. Combination and method-of-use patents may extend protection beyond the core compound, but their value is more vulnerable to label carve-outs, non-infringing use arguments, and clinical-practice variability. Manufacturing patents can raise the cost of entry but usually provide weaker protection than a valid composition patent.
When could gedatolisib lose exclusivity?
Gedatolisib has no established FDA exclusivity expiration date because it has not been approved.
If approved, the likely exclusivity framework would include:
- Five-year new chemical entity exclusivity if the FDA classifies the product as an eligible new chemical entity.
- Three-year exclusivity for certain applications containing new clinical investigations.
- Patent term adjustment or patent term extension, subject to statutory limits.
- Orphan-drug exclusivity only if the product receives an orphan designation and approval for a qualifying rare disease indication.
- Data and market exclusivity under applicable FDA rules.
The actual generic-entry date would depend on the approved indication, listed patents, patent-term calculations, litigation outcomes, regulatory exclusivity, and any settlement agreement with a generic applicant.
What generic entry risks exist?
Generic entry risk is currently remote because there is no approved product. The more immediate risk is clinical and commercial substitution by existing therapies.
If gedatolisib is approved, generic risk would likely develop in stages:
- Patent challenges after Orange Book listing.
- Paragraph IV certification by generic manufacturers.
- Hatch-Waxman litigation.
- Potential 30-month stay of approval, subject to statutory conditions.
- Launch under patent expiry, litigation settlement, or at-risk circumstances.
- Price erosion after multiple generic entrants.
Because gedatolisib is expected to be an intravenous product, manufacturing complexity may slow generic entry relative to a simple oral tablet. That barrier does not replace patent protection. Injectable generics can enter when the formulation, manufacturing process, and regulatory requirements are reproducible.
What litigation or settlement agreements affect gedatolisib?
No commercial patent litigation or generic settlement is expected before FDA approval and Orange Book listing. The program's relevant legal exposure is currently more likely to involve licensing rights, clinical-trial obligations, patent prosecution, and potential ownership or inventorship disputes than Hatch-Waxman litigation.
No public regulatory pathway supports a present Paragraph IV challenge to gedatolisib.
How strong is the gedatolisib patent estate?
The patent estate cannot be ranked as commercially strong or weak solely from the existence of development patents. Its strength will depend on whether a valid, enforceable composition-of-matter patent remains in force at approval and whether later patents provide meaningful protection for the commercial regimen.
A strong estate would include:
- A long-lived composition patent.
- Multiple independently valid formulation and manufacturing claims.
- Combination patents covering the actual approved regimen.
- Method-of-use claims aligned with the label.
- Claims difficult to avoid through alternative dosing or treatment sequencing.
A weaker estate would rely mainly on narrow method-of-use claims, combination claims involving commonly used agents, or manufacturing claims that can be designed around.
What is the likely commercial outlook?
Gedatolisib has meaningful market potential but a high execution burden. Its addressable disease is large, and the post-CDK4/6 setting has continuing unmet need. The drug's potential differentiation is broad PI3K/mTOR pathway suppression, which could support use beyond single-gene biomarker populations.
The main constraints are established competition, class toxicity, intravenous administration, and the need to demonstrate a clear benefit over endocrine combinations, AKT inhibition, PI3K inhibition, mTOR inhibition, chemotherapy, and newer targeted modalities.
A successful launch would likely require:
- Positive Phase 3 results.
- A label that supports broad post-CDK4/6 use.
- Manageable hyperglycemia and gastrointestinal toxicity.
- Evidence that treatment delays chemotherapy.
- Favorable payer positioning.
- A dosing schedule that limits infusion burden.
- Commercial support sufficient to compete with established products.
Key Takeaways
- Gedatolisib is an investigational PI3K/mTOR inhibitor with no FDA approval or product revenue as of June 2024.
- Its lead opportunity is HR-positive, HER2-negative metastatic breast cancer after CDK4/6 inhibitor progression.
- VIKTORIA-1 is the principal Phase 3 value driver.
- The drug may compete through broad pathway inhibition and potential biomarker flexibility.
- Approved competitors include alpelisib, capivasertib, everolimus, elacestrant, chemotherapy, and emerging antibody-drug conjugates.
- No Orange Book listing, Paragraph IV challenge, generic litigation, or FDA exclusivity expiration currently applies.
- Financial value depends primarily on Phase 3 success, safety, commercial differentiation, licensing economics, and future patent duration.
- Intravenous administration and PI3K/mTOR-class toxicity are the largest commercial constraints.
- The asset has substantial upside if it delays chemotherapy with tolerable toxicity, but its downside remains high because it has no approved revenue base.
FAQs
Is gedatolisib approved for breast cancer?
No. Gedatolisib had not received FDA approval as of June 2024 and remained in clinical development.
Is gedatolisib a PI3K inhibitor or an mTOR inhibitor?
It is both. Gedatolisib is designed to inhibit class I PI3K and mTOR signaling, giving it broader pathway coverage than selective PI3K inhibitors.
Can a generic company challenge gedatolisib today?
Not through a conventional Paragraph IV filing tied to an Orange Book listing, because gedatolisib has no FDA-approved product or Orange Book-listed patents.
Does gedatolisib compete with capivasertib?
Yes. Both are being positioned for advanced HR-positive, HER2-negative breast cancer after endocrine therapy and CDK4/6 inhibition, although capivasertib is an approved oral AKT inhibitor and gedatolisib remains investigational and intravenous.
What would most increase the value of gedatolisib?
A positive Phase 3 result showing meaningful progression-free or overall-survival improvement, broad eligibility beyond a narrow genomic subgroup, and manageable metabolic and gastrointestinal toxicity would provide the strongest increase in commercial value.
References
-
Celcuity, Inc. (2023). Form 10-K annual report. U.S. Securities and Exchange Commission.
-
ClinicalTrials.gov. (n.d.). A study of gedatolisib plus fulvestrant with or without palbociclib versus chemotherapy in participants with HR-positive, HER2-negative advanced or metastatic breast cancer: VIKTORIA-1. U.S. National Library of Medicine.
-
Food and Drug Administration. (2019). FDA approves alpelisib for metastatic breast cancer. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023). FDA approves capivasertib with fulvestrant for breast cancer. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Pfizer Inc. (2023). Form 10-K annual report. U.S. Securities and Exchange Commission.
